Cilostazol – 50 mg

Brand:
Cayman
CAS:
73963-72-1
Storage:
-20
UN-No:
Non-Hazardous - /

Cilostazol is a phosphodiesterase 3A (PDE3A) inhibitor (IC50 = 0.2 µM for the platelet enzyme).{54486} It is selective for PDE3A over PDE1, -2, -4, and -5 (IC50s = >5 µM for all). Cilostazol inhibits collagen- or ADP-induced aggregation of isolated rabbit platelets (IC50s = 29 and 31 µM, respectively).{23681} In vivo, cilostazol (30 mg/kg) reduces thrombus formation by 84% in a mouse model of pulmonary thromboembolism. It reduces cardiac fibrosis and prevents the development of diastolic dysfunction and cardiac hypertrophy induced by a high-fat diet and angiotensin II in mice.{54485} Formulations containing cilostazol have been used in the treatment of the symptoms of intermittent claudication in peripheral vascular disease.  

 

SKU: - Category:

Description

A PDE3A inhibitor (IC50 = 0.2 µM for the platelet enzyme); selective for PDE3A over PDE1, -2, -4, and 5 (IC50s = >5 µM for all); inhibits collagen- or ADP-induced aggregation of isolated rabbit platelets (IC50s = 29 and 31 µM, respectively); reduces thrombus formation by 84% in a mouse model of pulmonary thromboembolism at 30 mg/kg


Formal name: 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone

Synonyms:  OPC 13013|OPC 21|Pletaal|Pletal

Molecular weight: 369.5

CAS: 73963-72-1

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Phosphodiesterases||Research Area|Cardiovascular System|Blood|Coagulation & Hemostasis||Research Area|Cardiovascular System|Blood|Thrombosis||Research Area|Cardiovascular System|Heart|Myocardial Hypertrophy||Research Area|Cardiovascular System|Vasculature||Research Area|Cell Biology|Cell Signaling|cAMP Signaling||Research Area|Cell Biology|Cell Signaling|cGMP Signaling